In episode #91 of The Weekly Bioanalysis, John and Dom return to a two-person format to tackle the "gray areas" of bioanalysis, focusing on drug discovery, biomarkers, tissues, and emerging technologies. They discuss how traditional PK assay validation is highly standardized, but areas like early-stage discovery, biomarker qualification, and tissue analysis require more nuanced, fit-for-purpose approaches. A key theme is the need for flexibility and client collaboration, particularly when def...
In this episode of “The Weekly Bioanalysis” podcast, our hosts, Dominic Warrino and John Perkins, sit down with two key leaders shaping the company’s future — Maria Nelson, Chief Financial Officer, and Julie Deane, Chief People Officer — to discuss KCAS Bio’s strategy for balancing rapid growth with an exceptional employee experience. Building on the previous conversation with Jeff Goddard, this episode dives deeper into how KCAS Bio has evolved its people operations and operational planning....
In Episode 89 of The Weekly Bioanalysis, hosts Dominic Warrino and John Perkins engage in a compelling conversation with special guest, Jeff Goddard, Senior Vice President of Corporate Development at KCAS Bio. The three delve into KCAS Bio's strategic growth, including the acquisition of France-based Active Biomarkers, which expanded the company's transatlantic presence. Jeff shares insights into the evolving landscape of bioanalytical services and how KCAS Bio is positioning itself to meet t...
In Episode 88 of The Weekly Bioanalysis, hosts Dominic Warrino and John Perkins present a special WRIB 2025 recap featuring several KCAS Bio scientists who share firsthand insights from their presentations at the major bioanalytical conference. Dave Ambrose highlights KCAS Bio’s global harmonization of spectral flow cytometry instruments across sites in the U.S., France, and Australia, showcasing the industry’s first off-the-shelf spectral flow panel with impressively tight inter-site CVs. Je...
In episode 87 of The Weekly Bioanalysis podcast, John Perkins and Dawn Dufield preview the upcoming WRIB conference, where KCAS Bio and Sciex will both have strong representation through scientific presentations, panels, and business development efforts. Special guest, Rahul Baghla of Sciex, discusses the company’s collaboration with KCAS Bio and introduces their high-throughput Echo technology, which uses acoustic ejection to improve speed and reduce carryover in early discovery assays. The ...
During episode 86 of KCAS Bio's "The Weekly Bioanalysis" podcast, our hosts Dom and John are joined by Dr Cheikh Kane, the Vice President of Biopharma Services at KCAS Bio, to discuss immunogenicity. They first define Immunogenicity; what it is and why it is tested, as well as the standard approach for ADA testing before answering the question of "What is a 'Lean' anti-drug antibody (ADA) approach, and when should it be employed?". Dr Kane brings his decades of experience and biopharmaceutica...
Dom and John, the hosts of “The Weekly Bioanalysis”, recently returned from EBF in Barcelona where there was a session on Patient-centric Microsampling, which both of them founnd fascinating. This inspired both of them to decide it was high time to revisit this part of our industry. In spite of a few infamous setbacks caused by the dishonesty of a few bad actors within the industry a years ago, there has been a renewed interest in patient-centric sampling, and our hosts have invited one of th...
In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and how the evolving role of LC-MS continues to shape the industry. Parmentier emphasizes the value of pre-validation in ensuring method robustness and shares lessons learned from develop...
The 2024 tradeshow and conference season is finally coming to a close for the pharmaceutical and biotech industry, and our road-weary traveling hosts, Dom and John have returned from their final event, the 2024 European Bioanalysis Forum (EBF) Open Symposium in Barcelona, Spain. EBF was founded in 2006 at the initiative of 12 pharmaceutical companies. The goal was to create a platform for discussions around science, day-to-day procedures, business tools, technologies and - last but not least ...
It’s conference season! This is a busy, busy time of the year for the entire industry, when everyone comes together from around the world to share, listen and discuss the changes and advancements taking place in the business and science of the pharma and biotech space. During this episode of “The Weekly Bioanalysis”, our hosts, Dom and John, go over all the places – around the world – where the KCAS Bio team will be taking part in exhibitions, panels and presentations. From Europe to Australi...
After such a great response to our recent episode on the topic, our hosts, Dom and John, revisit the topic of GLP-1 Analogue development and the role bioanalysis plays in this relatively new and popular topic. In the words of John, “Everyone else is talking about this; why shouldn’t we?” And wow, do they have a lot to say about it on this second pass at the advances being made in this ever-growing and ever-changing field. The guys talk about the latest developments in the GLP-1 Analogue space...
Our hosts, Dom and John, are excited to welcome special guest, Carrie Vyhlidal, to discuss the topic of the 80th episode of “The Weekly Bioanalysis” podcast – The Rapid Evolution of PCR Assays. PCR (or Polymerase Chain Reaction) is like a copying machine for DNA. Scientists have found ways to measure the copies being made throughout the reactions, which is where they get their real-time, quantitative PCR (or qPCR). Carrie does a wonderful job of explaining not only why these advancements in t...
The most recent episode of "The Weekly Bioanalysis" podcast is all about genes today! The topic was originally inspired by an article entitled "The Coming of Age of One-and-Done Therapies" which jumped out to both of our hosts, Dom and John, and had been on the back burner for a while for them to discuss. With KCAS Bio housing entire departments specializing in bioanalysis, and given the recent rise of similar topics in the news, this seemed like the right time for the guys to chat about it. ...
Dom has been globe-trotting lately, and he has come back to report in on his adventures with John, as they discuss our global services here at KCAS Bio. They talk about the updates and the latest news from Lyon and the rollout of our collaboration with Crux Laboratories in Melbourne. Most notable was Dom’s trip to Lyon and some of the excitement he experienced there (spoiler: it involves tear gas!!). Our two hosts also discuss the strategy and growth of both our Lyon site, and the new things ...
Dom and John welcome special guests, Habibi Goudarzi and Rochelle Burke to episode #77 of "The Weekly Bioanalysis", where they discuss the progression of bioanalytical needs for non-GLP Studies, from Early PK to readiness for GLP Tox Studies. These specialists from the KCAS Bio team begin with an introduction to all things non-GLP and LC-MS. From there, they discuss the general need for speed and the workflow they have established at KCAS Bio to facilitate rapid turnaround for studies, as wel...
For episode #76 of "The Weekly Bioanalysis", Dom and John talk about the popular topic of GLP-1 Analogues - these series of recent blockbuster drugs with multiple applications, as well as some of their bioanalytical challenges. First, the guys go over a little bit of the mechanism of action of GLP-1's, then some of the rules around them and their initial diabetic treatments. They talk about the structures, and a little bit about how they are being used in weight loss (which, of course, is how...
CEO of KCAS Bio, John Bucksath, joins Dom and John for a special 75th episode of “The Weekly Bioanalysis” podcast, and he is absolutely delighted to use the special episode to talk about the recent rebrand of KCAS to KCAS Bio! Mr Bucksath and our hosts discuss the reason the rebrand came about, the process our organization took, and some of the initial reactions our team have experienced from our first few outings with the new look and name. Join us as we introduce the new brand and point to ...
During this episode of “The Weekly Bioanalysis”, Dom and John talk about addressing the needs of rare diseases - some challenges and industry trends they’ve watched take place, and they are joined by guest, Lindsay Rutherford, who has her own personal experience with rare disease and how it can impact lives. As a bioanalytical provider, KCAS Bio of course has a unique take on this topic as well, as rare disease has its own challenges in terms of small sample loads, rapid turnaround of samples...
To kick off the first episode of “The Weekly Bioanalysis” in 2024, Dom and John unveil some fun new things happening at KCAS, by talking about the parallel evolution of the bioanalytical industry and KCAS. Our hosts go way back – almost to “square one” (discussing “What is bioanalysis?” and “How has bioanalysis changed over the years?”. They take a nice little dip back into history and then and then tie it all back to where we are now and what it means about we are going for the future. We ho...
For the final episode of “The Weekly Bioanalysis” in 2023, Dom and John invited KCAS’s scientific advisory team to join them, as we thought that as we are coming to the end of the year, it might be a good opportunity to introduce a few members of the scientific advisory team who may be involved in some greater capacity with the podcast going forward, as the organization grows and expands. Then our hosts just have a chat about reviewing how 2023 went and what they see coming up in 2024 within ...